Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1268409 | 0.84 | DAO (0.55) | DAOMEN1KMT2APOLBCYP1A2 | |
| SCHEMBL8558924 | 0.81 | MEN1 (0.49) | DAOMEN1KMT2APOLBCYP1A2 | |
| SCHEMBL29654412 | 0.78 | PKM (0.42) | DAOMEN1KMT2ACYP1A2LMNA | |
| SCHEMBL17501689 | 0.78 | PKM (0.42) | DAOMEN1KMT2ACYP1A2LMNA | |
| SCHEMBL18948019 | 0.77 | CYP1A2 (0.60) | DAOMEN1KMT2APOLBCYP1A2 | |
| SCHEMBL3702314 | 0.75 | DAO (0.59) | DAOMEN1KMT2APOLBCYP1A2 | |
| SCHEMBL29695485 | 0.74 | MEN1 (0.62) | DAOMEN1KMT2APOLBCYP1A2 | |
| SCHEMBL4175626 | 0.74 | MEN1 (0.62) | DAOMEN1KMT2APOLBCYP1A2 | |
| SCHEMBL7092638 | 0.73 | CYP1A2 (0.51) | DAOMEN1KMT2APOLBCYP1A2 | |
| SCHEMBL29991182 | 0.72 | DAO (0.61) | DAOMEN1KMT2APOLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187723-B2 | Substituted benzimidazolone compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-07 | — | — | US | disclosed |
| EP-3965888-B1 | SUBSTITUTED BENZIMIDAZOLONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-08-21 | — | — | EP | disclosed |
| CN-114126713-B | Substituted benzimidazolone compounds | 百时美施贵宝公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20220289739-A1 | SUBSTITUTED BENZIMIDAZOLONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2022-09-15 | — | — | US | disclosed |
| EP-3965888-A1 | SUBSTITUTED BENZIMIDAZOLONE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114126713-A | Substituted benzimidazolone compounds | 百时美施贵宝公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20090069341-A1 | INHIBITORS OF HSP90 | CHENE PATRICK | 2009-03-12 | — | — | US | disclosed |
| US-7244744-B2 | Piperidines | ICAGEN, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-6506738-B1 | Treatment of viral infections. More particularly, the invention provides benzimidazolone derivatives for the treatment of respiratory syncytial virus infection. | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-14 | — | — | US | disclosed |
| WO-2002026228-A1 | BENZIMIDAZOLONE ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187723-B2 | Substituted benzimidazolone compounds | TLR7, TLR1, TLR9 | DAO 1103/4885MEN1 2845/4885KMT2A 3590/4885 |
| US-20090069341-A1 | INHIBITORS OF HSP90 | HSP90AB1, HSP90B1, HSP90AA1 | DAO 4513/4885MEN1 3761/4885KMT2A 4041/4885 |
| US-20220289739-A1 | SUBSTITUTED BENZIMIDAZOLONE COMPOUNDS | TLR7, TLR1, TLR9 | DAO 1103/4885MEN1 2845/4885KMT2A 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.